About Resverlogix

Donald McCaffrey

President & Chief Executive Officer

Mr. McCaffrey is President and Chief Executive Officer of Resverlogix Corp. He has over 40 years of corporate management experience including over 20 years in drug discovery & development. Don co-founded Resverlogix in 2001 with Dr. Norman Wong. His expertise in corporate operations has attracted an international team of experts to the company, including world renowned Key Opinion Leaders in the fields of cardiology, endocrinology, and nephrology. Due to Don’s efforts, the company’s lead drug – apabetalone (RVX-208) – has an 8-year lead on the market as the first epigenetic drug for the reduction of major adverse cardiac events. Don has directed the company in its continued partnering discussions with global pharmaceutical companies, establishing one of the largest China biotech partnerships to date with Shenzhen Hepalink Pharmaceuticals. Don is also the co-founder, President and CEO of Zenith Epigenetics, a private, clinical stage biotechnology company focused on the discovery and development of novel therapeutics for the treatment of cancer and other disorders with significant unmet medical need. He successfully negotiated Zenith’s ongoing partnerships and collaborations with Pfizer, Merck, Astellas, AstraZeneca, Eli Lilly & Company, Bristol Myers Squibb, and Newsoara Biopharma.

Don’s passion lies in supporting non-profit organizations, especially those that support education and the development of future generations of young scientists. Don’s personal donation to the Mount Royal University contributed to the Roderick Mah Centre for Continuous Learning, which supports student facilities within the health and sciences programs.

Dr. Ewelina Kulikowski, Ph.D.

Chief Scientific Officer

Ewelina Kulikowski serves as Chief Scientific Officer at Resverlogix, where she directs the company’s scientific strategy, contributes to commercialization and lifecycle planning, and oversees all research and development activities. Dr. Kulikowski is also Resverlogix’ primary scientific communicator. She shares our latest program developments in presentations at scientific conferences, as well as in discussions with investors and partners.

Since joining the company in 2005, Dr. Kulikowski has contributed to the development of lead drug apabetalone (RVX-208) from its discovery, through preclinical evaluation, an investigational new drug application, and the completion of multiple human clinical studies. She led projects that demonstrated apabetalone’s therapeutic potential in vascular disease, pulmonary hypertension, muscular dystrophy, and COVID-19, as well as projects that uncovered apabetalone’s unique epigenetic mechanism of action. This work resulted in the publication of over 25 peer-reviewed articles and numerous successful patent applications.

Dr. Kulikowski holds a Doctorate in Oncology from the University of Calgary, Alberta. She enjoys cycling and hiking, is fluent in Polish and an active member of the Calgary Polish community.

Brad Cann, CPA, CA, CBV

Chief Financial Officer

Brad has more than 25 years of experience with more than 20 years in senior management roles. Prior to joining Resverlogix in 2009, Brad was Executive Vice President and CFO of Royal Host Real Estate Investment Trust. Between 2000 and 2004, he was a business consultant and held senior management positions. Between 1995 and 2000, Mr. Cann held various positions with a regional accounting firm.

Mr. Cann is a Chartered Professional Accountant, a Chartered Business Valuator, and holds a Bachelor of Commerce from the University of Saskatchewan.

Brad is an avid cyclist and triathlete.

Dr. Michael Sweeney, M.D.

Senior Vice President, Clinical Development

Dr. Sweeney, a cardiologist, has a career spanning over 25 years in the pharmaceutical industry, including 11 years at Pfizer Inc., holding a variety of senior-level medical and marketing positions, including Senior Director, Urology Global Medical Group Leader and Director of Marketing of the Viagra® Worldwide Team. Prior to joining Resverlogix, Dr. Sweeney was Chief Medical Officer and Vice President of Research and Development at Depomed, Inc. in California. Dr. Sweeney was also the Vice President of Medical Affairs at CV Therapeutics, Inc., where he built the medical affairs department to enable the successful launch of Ranexa® for patients with cardiovascular disease and chronic angina.

Dr. Sweeney holds biochemistry and medical degrees from Liverpool University and an advanced medical research degree from Manchester University in the U.K. Dr. Sweeney also holds post-graduate diplomas in pharmaceutical medicine and pharmaco-epidemiology from the University of London. He is a fellow of the Royal College of Physicians of Edinburgh.

Mike enjoys swimming, cycling, football, the cinema and travelling with his family.

Dr. Henrik C. Hansen, Ph.D.

Vice President, Intellectual Property

Dr. Hansen joined Resverlogix in 2005 and has over 20 years of experience from both academia and industry in basic research, drug discovery and drug development. His areas of expertise include drug discovery, medicinal chemistry, process development and manufacturing of drug substances and drug products under cGMP for clinical use. Dr. Hansen is the inventor of apabetalone (RVX-208).

Dr. Hansen holds a M.Sc. in Chemical Engineering from the Technical University of Denmark and a Ph.D. in Organic Chemistry from Lund University, Sweden. He has authored or co-authored more than 70 articles and meeting abstracts and is listed as the inventor of 12 patent families.

Henrik is an active runner and nature photographer.

Dr. Ravi Jahagirdar, DVM, MS

Vice President, Pharmacology, Toxicology & Safety

Dr. Jahagirdar joined Resverlogix in 2004 and has more than 25 years of experience from both academia and industry. His areas of expertise include animal physiology, lipoprotein metabolism, pharmacology, toxicology, DMPK and basic research.

Dr. Jahagirdar played a key role in all aspects of the development of apabetalone and will continue to focus on strategic leadership in the implementation of toxicology and preclinical/clinical pharmacology activities to ensure safety and support of regulatory interactions.

Prior to joining Resverlogix, Dr. Jahagirdar held positions of increasing responsibility at University of Regina, and Tularik Inc. (Amgen). His research has been published in many peer-reviewed journals and has co-authored a textbook chapter and has numerous abstract presentations.

Dr. Jahagirdar obtained his Doctor of Veterinary Medicine from Veterinary College, Bangalore and a MS in Molecular Biology/Microbiology from Memorial University, Newfoundland.